Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.
第一作者:
Robert O,Hughes
第一单位:
Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, MO 63017, USA. robert.o.hughes@pfizer.com
作者:
主题词
投药, 口服(Administration, Oral);氨基吡啶类(Aminopyridines);动物(Animals);化学, 药物(Chemistry, Pharmaceutical);环GMP(Cyclic GMP);环核苷酸磷酸二酯酶类, 5型(Cyclic Nucleotide Phosphodiesterases, Type 5);药物设计(Drug Design);人类(Humans);氢离子浓度(Hydrogen-Ion Concentration);高血压(Hypertension);微粒体(Microsomes);模型, 化学(Models, Chemical);磷酸二酯酶5抑制剂(Phosphodiesterase 5 Inhibitors);磷酸二酯酶抑制剂(Phosphodiesterase Inhibitors);吡嗪类(Pyrazines);大鼠(Rats);大鼠, Sprague-Dawley(Rats, Sprague-Dawley);溶解度(Solubility)
DOI
10.1016/j.bmcl.2009.06.004
PMID
19539468
发布时间
2013-11-21
- 浏览25
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文